PL377606A1 - Postaci dawkowane zawierające inhibitor CETP i inhibitor reduktazy HMG-CoA - Google Patents
Postaci dawkowane zawierające inhibitor CETP i inhibitor reduktazy HMG-CoAInfo
- Publication number
- PL377606A1 PL377606A1 PL377606A PL37760603A PL377606A1 PL 377606 A1 PL377606 A1 PL 377606A1 PL 377606 A PL377606 A PL 377606A PL 37760603 A PL37760603 A PL 37760603A PL 377606 A1 PL377606 A1 PL 377606A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- hmg
- dosage forms
- coa reductase
- cetp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43534502P | 2002-12-20 | 2002-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL377606A1 true PL377606A1 (pl) | 2006-02-06 |
Family
ID=32682223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL377606A PL377606A1 (pl) | 2002-12-20 | 2003-12-12 | Postaci dawkowane zawierające inhibitor CETP i inhibitor reduktazy HMG-CoA |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7897175B2 (pl) |
| EP (1) | EP1581210B1 (pl) |
| JP (1) | JP2006512359A (pl) |
| KR (1) | KR20050088190A (pl) |
| CN (1) | CN1728995A (pl) |
| AR (1) | AR042534A1 (pl) |
| AT (1) | ATE389396T1 (pl) |
| AU (1) | AU2003286372A1 (pl) |
| BR (1) | BR0317593A (pl) |
| CA (1) | CA2509688A1 (pl) |
| CO (1) | CO5590898A2 (pl) |
| DE (1) | DE60319877T2 (pl) |
| ES (1) | ES2300628T3 (pl) |
| GT (1) | GT200300295A (pl) |
| IL (1) | IL169090A0 (pl) |
| NL (1) | NL1025070C (pl) |
| NO (1) | NO20052779L (pl) |
| PE (1) | PE20040970A1 (pl) |
| PL (1) | PL377606A1 (pl) |
| RU (1) | RU2005119176A (pl) |
| TW (1) | TW200420301A (pl) |
| UY (1) | UY28134A1 (pl) |
| WO (1) | WO2004056359A1 (pl) |
| ZA (1) | ZA200504123B (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| CZ20033341A3 (cs) * | 2001-06-21 | 2004-10-13 | Pfizeráproductsáinc | Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru |
| WO2003000226A2 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| RU2375046C2 (ru) * | 2004-10-25 | 2009-12-10 | Джапан Тобакко Инк. | Твердый состав с улучшенными растворимостью и стабильностью и способ его получения |
| ES2328384T3 (es) * | 2004-11-23 | 2009-11-12 | Warner-Lambert Company Llc | Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia. |
| US20090169583A1 (en) * | 2005-02-08 | 2009-07-02 | Pfizer, Inc. | Solid Adsorbates of Hydrophobic Drugs |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| WO2006129167A1 (en) * | 2005-05-31 | 2006-12-07 | Pfizer Products Inc. | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS |
| EP1912625B1 (en) | 2005-08-08 | 2016-04-13 | AbbVie Deutschland GmbH & Co KG | Itraconazole compositions with improved bioavailability |
| WO2007017249A1 (en) * | 2005-08-08 | 2007-02-15 | Abbott Gmbh & Co. Kg | Dosage forms with improved bioavailability |
| DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
| US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
| KR100791256B1 (ko) * | 2006-03-17 | 2008-01-03 | 주식회사 대웅제약 | 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물 |
| US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
| EP2081554A2 (en) * | 2006-09-27 | 2009-07-29 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
| AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
| WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| EA025649B1 (ru) * | 2010-11-04 | 2017-01-30 | Ф.Хоффманн-Ля Рош Аг | Таблетка, содержащая s-[2-([[1-(2-этилбутил)циклогексил]карбонил]амино)фенил]-2-метилпропантиоат и кроскарамеллозу натрия |
| KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
| WO2016032324A1 (en) * | 2014-08-28 | 2016-03-03 | Dezima Pharma B.V. | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS |
| JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| CA2150372C (en) | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
| CA2222811C (en) * | 1995-06-01 | 2008-09-30 | G.D. Searle & Co. | Stabilized solid dispersions of misoprostol |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| AU7706598A (en) * | 1997-05-30 | 1998-12-30 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
| US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| WO2000038722A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
| EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| ES2215050T3 (es) * | 2000-06-09 | 2004-10-01 | Lek Pharmaceutical And Chemical Co. D.D. | Composicion estabilizada farmaceuticamente eficaz y formulacion farmaceutica que la comprende. |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| AU2001270937A1 (en) * | 2000-08-15 | 2002-02-25 | Pfizer Products Inc. | Therapeutic combination |
| US20020077348A1 (en) | 2000-11-21 | 2002-06-20 | Dean Herbert M. | Dosage unit for cardioprotection |
| DE60219307T2 (de) * | 2001-06-12 | 2008-01-10 | Galephar M/F | Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| BR0317521A (pt) | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa |
| US20040132771A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
-
2003
- 2003-12-12 DE DE60319877T patent/DE60319877T2/de not_active Revoked
- 2003-12-12 CA CA002509688A patent/CA2509688A1/en not_active Abandoned
- 2003-12-12 PL PL377606A patent/PL377606A1/pl not_active Application Discontinuation
- 2003-12-12 ES ES03777117T patent/ES2300628T3/es not_active Expired - Lifetime
- 2003-12-12 EP EP03777117A patent/EP1581210B1/en not_active Revoked
- 2003-12-12 CN CNA2003801069589A patent/CN1728995A/zh active Pending
- 2003-12-12 RU RU2005119176/15A patent/RU2005119176A/ru not_active Application Discontinuation
- 2003-12-12 BR BR0317593-6A patent/BR0317593A/pt not_active IP Right Cessation
- 2003-12-12 WO PCT/IB2003/006087 patent/WO2004056359A1/en active IP Right Grant
- 2003-12-12 AU AU2003286372A patent/AU2003286372A1/en not_active Abandoned
- 2003-12-12 AT AT03777117T patent/ATE389396T1/de not_active IP Right Cessation
- 2003-12-12 KR KR1020057011269A patent/KR20050088190A/ko not_active Application Discontinuation
- 2003-12-12 JP JP2004561902A patent/JP2006512359A/ja active Pending
- 2003-12-18 AR ARP030104713A patent/AR042534A1/es unknown
- 2003-12-18 NL NL1025070A patent/NL1025070C/nl not_active IP Right Cessation
- 2003-12-18 US US10/739,567 patent/US7897175B2/en not_active Expired - Fee Related
- 2003-12-18 UY UY28134A patent/UY28134A1/es not_active Application Discontinuation
- 2003-12-18 TW TW092135977A patent/TW200420301A/zh unknown
- 2003-12-19 GT GT200300295A patent/GT200300295A/es unknown
-
2004
- 2004-01-05 PE PE2004000021A patent/PE20040970A1/es not_active Application Discontinuation
-
2005
- 2005-05-20 ZA ZA200504123A patent/ZA200504123B/en unknown
- 2005-06-08 NO NO20052779A patent/NO20052779L/no not_active Application Discontinuation
- 2005-06-09 IL IL169090A patent/IL169090A0/en unknown
- 2005-06-17 CO CO05059491A patent/CO5590898A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NL1025070C (nl) | 2010-04-06 |
| WO2004056359A1 (en) | 2004-07-08 |
| CN1728995A (zh) | 2006-02-01 |
| BR0317593A (pt) | 2005-11-22 |
| US20040197398A1 (en) | 2004-10-07 |
| ZA200504123B (en) | 2006-02-22 |
| NO20052779D0 (no) | 2005-06-08 |
| AR042534A1 (es) | 2005-06-22 |
| NL1025070A1 (nl) | 2004-06-22 |
| UY28134A1 (es) | 2004-07-30 |
| TW200420301A (en) | 2004-10-16 |
| EP1581210A1 (en) | 2005-10-05 |
| ATE389396T1 (de) | 2008-04-15 |
| ES2300628T3 (es) | 2008-06-16 |
| RU2005119176A (ru) | 2006-01-20 |
| AU2003286372A1 (en) | 2004-07-14 |
| NO20052779L (no) | 2005-08-25 |
| DE60319877T2 (de) | 2009-04-30 |
| CA2509688A1 (en) | 2004-07-08 |
| US7897175B2 (en) | 2011-03-01 |
| EP1581210B1 (en) | 2008-03-19 |
| DE60319877D1 (de) | 2008-04-30 |
| CO5590898A2 (es) | 2005-12-30 |
| IL169090A0 (en) | 2007-07-04 |
| JP2006512359A (ja) | 2006-04-13 |
| GT200300295A (es) | 2004-08-18 |
| KR20050088190A (ko) | 2005-09-02 |
| PE20040970A1 (es) | 2004-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL169090A0 (en) | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor | |
| HK1080734A1 (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
| PL359820A1 (pl) | Inhibitory reduktazy HMG-CoA i sposób leczenia | |
| IL163929A0 (en) | Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulinsensitizer | |
| EP1684754A4 (en) | HMG COA REDUCTASE INHIBITORS AND METHOD | |
| IL166279A0 (en) | Composition comprising a cholesterol absorption inhibitor an HMG-COA reductase inhibitor and a stabilizing agent | |
| GB2384947B (en) | Enabling and/or inhibiting an operation of a wireless communicatons unit | |
| DE60202452D1 (de) | Pyridazinonaldose reductase inhibitoren | |
| NO20026011D0 (no) | HMG-CoA-reduktase-inhibitorer og fremgangsmåte | |
| GB0205527D0 (en) | Inhibitors | |
| AP2005003251A0 (en) | New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors. | |
| GB2412372B (en) | Pyrazine-based tubulin inhibitors | |
| AU2003220437A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
| AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
| AU2003237739A1 (en) | Combination of a reflux inhibitor and an imidazopyridine for the treatment of gerd | |
| PL371217A1 (pl) | Inhibitory integryny alfaVbeta6 | |
| EP1570847A4 (en) | PHOSPHODIESTERASE 10A HEMMER | |
| AU2003236636A1 (en) | COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER | |
| AU2003256323A8 (en) | Sos1 inhibitors | |
| IL154927A0 (en) | Combination of statins and sorbitol dehydrogenase inhibitors | |
| AU2003267790A8 (en) | Lipase inhibitors and uses thereof | |
| HK1077230A1 (en) | Medicinal composition hmg-coa reductase inhibitor | |
| HUP0201597A3 (en) | Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines | |
| GB0220776D0 (en) | FOXP2 and uses thereof | |
| GB0001565D0 (en) | Dihydrofolate reductase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |